• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伊马替尼治疗肾源性系统性纤维化

Imatinib in the treatment of nephrogenic systemic fibrosis.

作者信息

Chandran Sindhu, Petersen Jeffrey, Jacobs Charlotte, Fiorentino David, Doeden Katherine, Lafayette Richard A

机构信息

Division of Nephrology, Stanford University, Stanford, CA 94305-5114, USA.

出版信息

Am J Kidney Dis. 2009 Jan;53(1):129-32. doi: 10.1053/j.ajkd.2008.08.029. Epub 2008 Nov 13.

DOI:10.1053/j.ajkd.2008.08.029
PMID:19012999
Abstract

Nephrogenic systemic fibrosis is a disabling progressive condition that is being reported with increased frequency in patients with kidney disease. Treatment is extremely limited and largely supportive. We report a case of severe nephrogenic systemic fibrosis in a dialysis patient exposed to multiple doses of gadolinium who improved clinically and histologically with treatment with imatinib.

摘要

肾源性系统性纤维化是一种致残性进行性疾病,在肾病患者中的报告频率日益增加。治疗方法极为有限,主要是支持性治疗。我们报告了一例接受多次钆剂注射的透析患者发生严重肾源性系统性纤维化的病例,该患者经伊马替尼治疗后临床和组织学表现均有改善。

相似文献

1
Imatinib in the treatment of nephrogenic systemic fibrosis.伊马替尼治疗肾源性系统性纤维化
Am J Kidney Dis. 2009 Jan;53(1):129-32. doi: 10.1053/j.ajkd.2008.08.029. Epub 2008 Nov 13.
2
Evaluation of imatinib mesylate as a possible treatment for nephrogenic systemic fibrosis in a rat model.甲磺酸伊马替尼治疗肾源性系统性纤维化大鼠模型的评价。
Magn Reson Imaging. 2013 Jan;31(1):139-44. doi: 10.1016/j.mri.2012.06.027. Epub 2012 Aug 13.
3
Nephrogenic systemic fibrosis: is gadolinium to be blamed?肾源性系统性纤维化:钆对比剂是罪魁祸首吗?
J Assoc Physicians India. 2008 Nov;56:915-6.
4
Antifibrotic effect after low-dose imatinib mesylate treatment in patients with nephrogenic systemic fibrosis: an open-label non-randomized, uncontrolled clinical trial.低剂量甲磺酸伊马替尼治疗肾源性系统性纤维化患者的抗纤维化作用:一项开放标签非随机对照临床试验。
J Eur Acad Dermatol Venereol. 2013 Jun;27(6):779-84. doi: 10.1111/j.1468-3083.2011.04398.x. Epub 2011 Dec 20.
5
Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction.肾源性系统性纤维化:一种与钆相关的肾功能不全患者的纤维化疾病。
Ann Rheum Dis. 2008 Dec;67 Suppl 3:iii66-9. doi: 10.1136/ard.2008.102475.
6
Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease.终末期肾病透析患者静脉注射钆造影剂后 NSF 的发生率。
Eur J Radiol. 2010 Oct;76(1):129-34. doi: 10.1016/j.ejrad.2009.06.028. Epub 2009 Jul 19.
7
Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis?组织钆沉积和纤维化类似于肾源性系统性纤维化(NSF)-亚临床肾源性系统性纤维化?
J Am Acad Dermatol. 2010 Feb;62(2):337-42. doi: 10.1016/j.jaad.2009.04.010. Epub 2009 Nov 24.
8
Gadolinium-associated nephrogenic systemic fibrosis.钆相关的肾源性系统性纤维化。
Am Fam Physician. 2009 Oct 1;80(7):711-4.
9
Correction to the relative risk calculation for gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis.钆增强磁共振成像与肾源性系统性纤维化相对风险计算的校正
Radiology. 2010 Apr;255(1):307-8; author reply 308. doi: 10.1148/radiol.091726.
10
Gadolinium and systemic fibrosis: guilt by association.钆与系统性纤维化:因关联而获罪。
Ann Rheum Dis. 2010 Nov;69(11):1895-7. doi: 10.1136/ard.2010.134791.

引用本文的文献

1
The Clinical Manifestations and Efficacy of Different Treatments Used for Nephrogenic Systemic Fibrosis: A Systematic Review.肾源性系统性纤维化不同治疗方法的临床表现及疗效:一项系统评价
Int J Nephrol Renovasc Dis. 2023 Jan 12;16:17-30. doi: 10.2147/IJNRD.S392231. eCollection 2023.
2
Cutaneous Manifestations of Chronic Kidney Disease, Dialysis and Post-Renal Transplant: A Review.慢性肾脏病、透析及肾移植术后的皮肤表现:综述
Indian J Dermatol. 2021 Jan-Feb;66(1):3-11. doi: 10.4103/ijd.IJD_502_20.
3
Chelation of gadolinium with deferoxamine in a patient with nephrogenic systemic fibrosis.
在一名患有肾源性系统性纤维化的患者中钆与去铁胺的螯合作用。
NDT Plus. 2009 Aug;2(4):309-11. doi: 10.1093/ndtplus/sfp042. Epub 2009 Apr 23.
4
Renal effects of targeted anticancer therapies.靶向抗癌疗法的肾脏效应。
Nat Rev Nephrol. 2015 Jun;11(6):354-70. doi: 10.1038/nrneph.2015.15. Epub 2015 Mar 3.
5
Cutaneous manifestations of ESRD.终末期肾病的皮肤表现。
Clin J Am Soc Nephrol. 2014 Jan;9(1):201-18. doi: 10.2215/CJN.05900513. Epub 2013 Oct 10.
6
Targeting the PDGF signaling pathway in the treatment of non-malignant diseases.靶向血小板衍生生长因子(PDGF)信号通路治疗非恶性疾病。
J Neuroimmune Pharmacol. 2014 Mar;9(2):69-79. doi: 10.1007/s11481-013-9484-2. Epub 2013 Jun 25.
7
Nephrogenic systemic fibrosis.肾源性系统性纤维化
Indian Dermatol Online J. 2011 Jul;2(2):51-6. doi: 10.4103/2229-5178.85990.
8
Imatinib ameliorates renal morphological changes in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension.伊马替尼可改善可诱导的 ANG II 依赖性恶性高血压 Cyp1a1-Ren2 转基因大鼠的肾脏形态学变化。
Am J Physiol Renal Physiol. 2012 Jan 1;302(1):F60-9. doi: 10.1152/ajprenal.00218.2011. Epub 2011 Oct 5.
9
Comparison of imatinib, nilotinib and silymarin in the treatment of carbon tetrachloride-induced hepatic oxidative stress, injury and fibrosis.比较伊马替尼、尼洛替尼和水飞蓟素治疗四氯化碳诱导的肝氧化应激、损伤和纤维化。
Toxicol Appl Pharmacol. 2011 Apr 15;252(2):165-75. doi: 10.1016/j.taap.2011.02.004. Epub 2011 Feb 24.
10
Immunotherapy of systemic sclerosis.系统性硬化症的免疫治疗。
Immunotherapy. 2010 Nov;2(6):863-78. doi: 10.2217/imt.10.69.